Guardant Health (GH) Stock Could Be Undervalued Despite Its 5x Run

Guardant Health has turned into one of the stronger movers in U.S. healthcare, with the share price now reflecting very optimistic expectations in the eyes of many investors. With that backdrop, the central question is whether the current valuation is properly supported by the cash flows the business can generate over time.

• The stock has delivered a very large 3 year return of about 5x, which puts real pressure on the cash flow story to support such a move.
• Recent coverage gains for Guardant Health’s Shield blood test expand the pool of eligible patients, which can influence how quickly future cash inflows may scale relative to the investment already made in the platform.
• If you'd rather focus on sales, this one's for you. See why Guardant Health's 20.1x P/S tells a different valuation story.

The issue now is whether Guardant Health’s current share price can be justified by the intrinsic value suggested by its cash flows.

If you want a yardstick for Guardant Health’s cash flow story, it can help to set it alongside other testing and diagnostics players using 38 healthcare AI stocks

Is Guardant Health Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash Guardant Health can generate for shareholders over time. Latest twelve month free cash flow sits at a loss of $232.9 million, so the whole valuation hinges on the shift implied in the forecast, where analysts expect the business to move into positive free cash flow and then grow it meaningfully over the coming decade.

Those projections assume that Guardant Health moves from loss making cash flows to several hundred million dollars of annual free cash generation by the early 2030s. This goes a long way to explaining why the DCF outcome sits meaningfully above the current share price of $177.25. Because the Shield blood test won broader coverage in EviCore guidelines for colorectal cancer screening, the model is effectively treating today’s cash burn as the price paid for a much larger future cash stream. Find out what Guardant Health could be worth using our Discounted Cash Flow (DCF) estimate.

The Guardant Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Guardant Health extend the cash flow puzzle into a clear set of testable assumptions about the company’s future growth, margins and earnings, so you can see what would need to happen for the stock to be worth materially more or less than today’s price on the Community page. Where a single valuation ratio or DCF output gives one headline figure, Narratives unpack the specific future path that figure relies on so you can watch how reality compares over time.

Bulls and bears on Guardant Health are looking at the same Shield and oncology story, but reaching very different value calls.

Bull case: 9% undervalued

"Rapid integration of AI-powered clinical analytics and multi-omic profiling into Guardant's Smart Liquid Biopsy platform is creating new clinical applications, enhancing product utility and differentiation versus peers..."

Discover why this Narrative puts Guardant Health at 9% undervalued.

Bear case: 17% overvalued

"Reliance on premium Medicare ADLT pricing for Shield at US$1,495 and very limited commercial reimbursement means any shift in payer mix toward commercial patients or slower than hoped contracting could compress Shield ASPs and limit revenue growth from screening..."

Explore why this Narrative puts Guardant Health at 17% overvalued.

Guardant Health’s valuation leaves one more crucial angle unexplored

Before you weigh Guardant Health purely on cash flows and narratives, it is worth checking the specific operational and financial red flags our research has highlighted for this business. Take a closer look at 2 warning signs (1 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com